A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presen...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova
Médium: Artigo
Jazyk:Russo
Vydáno: Remedium Group LLC 2018-07-01
Edice:Медицинский совет
Témata:
pemribrolizumab
non-small cell lung cancer
pd-1
pd-l1
On-line přístup:https://www.med-sovet.pro/jour/article/view/2526
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky